source
- Bristol Myers' lung drug admilparant meets Phase 3 goal at low dose, high dose falls shortBristol Myers Squibb reported that its experimental idiopathic pulmonary fibrosis therapy admilparant achieved its primary endpoint in a Phase 3 trial, showing a statistically significant slowing o…
- Bristol Myers reports two Phase 3 successes for fibrosis and RayzeBio drugBristol Myers Squibb announced Monday that two of its late-stage trials have met primary endpoints. The first trial involved its fibrosis program, where the experimental therapy demonstrated the e…